Evidence map›Paper›PMID 34589902›Full record

ArticleBrain, behavior, & immunity - health2020

Memantine can protect against inflammation-based cognitive decline in geriatric depression.

Kathleen Van Dyk, Prabha Siddarth, Maura Rossetti, Linda M Ercoli, Michaela M Milillo, Helen Lavretsky

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, & immunity - health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01902004 (Treatment of Geriatric Depression With Mild Cognitive Impairment), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01902004 phase4completednot on this map

Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age

TypeinterventionalSponsorUniversity of California, Los AngelesRan2013 to 2019Enrolled115ConditionsMild Cognitive Impairment (MCI), DepressionArmsEscitalopram, Memantine, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kathleen Van DykSemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA, USA.
Prabha SiddarthSemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA, USA.
Maura RossettiUCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Linda M ErcoliSemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA, USA.
Michaela M MililloSemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA, USA.
Helen LavretskySemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA, USA.
University of California, Los Angeles · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Brain aging and treatment response in geriatric depressionR01MH097892 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2013 to 2017
$3.5M
Mentoring and Research in Translational Science of Integrative MedicineK24AT009198 · NCCIH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Helen Lavretsky · 2016 to 2026
$1.4M
Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine TherapyK08CA241337 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DYK, KATHLEEN · 2019 to 2023
$925k
NCATS NIH HHS UL1 TR001881NCCIH NIH HHS K24 AT009198NCI NIH HHS K08 CA241337NIMH NIH HHS R01 MH097892
6 · The paper itself

Abstract

introductionGeriatric depression is frequently accompanied by cognitive complaints and inflammation that increase risk for treatment-resistant depression and dementia. Memantine, a neuroprotective drug, can improve depression, inflammation, and help prevent cognitive decline. In our six-month clinical trial, escitalopram/memantine (ESC/MEM) improved mood and cognition compared to escitalopram/placebo treatment (ESC/PBO; NCT01902004). In this report, we examined the impact of baseline inflammation on mood and cognitive outcomes. MATERIALS AND

methodsWe measured a panel of inflammatory cytokine markers using Human 38-plex magnetic cytokine/chemokine kits (EMD Millipore, HCYTMAG-60K-PX38) in 90 older adults 60 years and older with major depression enrolled in a 6-month double-blind placebo-controlled trial of escitalopram ​+ ​memantine (ESC/MEM) in depressed older adults with subjective memory complaints. Four cytokine factors were derived and linear models were estimated to examine the predictive ability of cytokine levels on treatment induced change in depression and cognition.

resultsOf the 90 randomized participants, 62 completed the 6-month follow up assessment. Both groups improved significantly on depression severity (HAM-D score), but not on cognitive outcomes at six months. Cytokine factor scores were not significantly different between ESC/MEM (n ​= ​45) and ESC/PBO (n ​= ​45) at baseline. Pro-inflammatory biomarkers at baseline predicted a decline in executive functioning in the ESC/PBO group but not in the ESC/MEM group, interaction F(1,52) ​= ​4.63, p ​= ​.04. DISCUSSION: In this exploratory analysis, the addition of memantine to escitalopram provided a protective effect on executive functioning in older depressed adults. Future studies are needed to replicate the association of cytokine markers to antidepressant and neuroprotective treatment-related change in cognition in geriatric depression.

Indexed as

Cognitive declineEscitalopramGeriatric depressionInflammationMemantine

Identifiers

PMID34589902
PMCPMC8474499
OpenAlexW3097418591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.